Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 515

1.

Natural alkaloid and polyphenol compounds targeting lipid metabolism: Treatment implications in metabolic diseases.

Cheng C, Li Z, Zhao X, Liao C, Quan J, Bode AM, Cao Y, Luo X.

Eur J Pharmacol. 2020 Mar 5;870:172922. doi: 10.1016/j.ejphar.2020.172922. Epub 2020 Jan 11. Review.

PMID:
31935398
2.

Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.

Zhang T, Wang Q, Ma WY, Wang K, Chang X, Johnson ML, Bai R, Bode AM, Foster NR, Falk GW, Limburg PJ, Iyer PG, Dong Z.

EBioMedicine. 2019 Nov;49:145-156. doi: 10.1016/j.ebiom.2019.10.038. Epub 2019 Nov 7.

3.

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.

Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, Litzow MR, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L.

Nat Commun. 2019 Nov 7;10(1):5051. doi: 10.1038/s41467-019-12960-6.

4.

Trichothecin inhibits invasion and metastasis of colon carcinoma associating with SCD-1-mediated metabolite alteration.

Liao C, Li M, Li X, Li N, Zhao X, Wang X, Song Y, Quan J, Cheng C, Liu J, Bode AM, Cao Y, Luo X.

Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158540. doi: 10.1016/j.bbalip.2019.158540. Epub 2019 Oct 31.

5.

Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-kB Activity in Triple-Negative Breast Cancer Cells.

Ma C, Zu X, Liu K, Bode AM, Dong Z, Liu Z, Kim DJ.

Mol Cells. 2019 Sep 30;42(9):628-636. doi: 10.14348/molcells.2019.0038.

6.

Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.

Zhang T, Bai R, Wang Q, Wang K, Li X, Liu K, Ryu J, Wang T, Chang X, Ma W, Bode AM, Xia Q, Song Y, Dong Z.

Cancer Prev Res (Phila). 2019 Dec;12(12):837-848. doi: 10.1158/1940-6207.CAPR-19-0211. Epub 2019 Sep 25.

PMID:
31554629
7.

Scutellarin Suppresses Patient-Derived Xenograft Tumor Growth by Directly Targeting AKT in Esophageal Squamous Cell Carcinoma.

Liu F, Zu X, Xie X, Zhang Y, Liu K, Chen H, Wang T, Bode AM, Dong Z, Kim DJ.

Cancer Prev Res (Phila). 2019 Dec;12(12):849-860. doi: 10.1158/1940-6207.CAPR-19-0244. Epub 2019 Sep 25.

PMID:
31554627
8.

The Role of Deubiquitinases in Oncovirus and Host Interactions.

Li Y, Shi F, Hu J, Xie L, Bode AM, Cao Y.

J Oncol. 2019 Jul 18;2019:2128410. doi: 10.1155/2019/2128410. eCollection 2019. Review.

9.

Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer.

Cheng C, Zhuo S, Zhang B, Zhao X, Liu Y, Liao C, Quan J, Li Z, Bode AM, Cao Y, Luo X.

Int J Biol Sci. 2019 Jun 4;15(8):1654-1663. doi: 10.7150/ijbs.33837. eCollection 2019. Review.

10.

CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.

Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, Bode AM, Dong Z.

Carcinogenesis. 2019 Jun 25. pii: bgz113. doi: 10.1093/carcin/bgz113. [Epub ahead of print]

PMID:
31241130
11.

Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells.

Zu X, Xie X, Zhang Y, Liu K, Bode AM, Dong Z, Kim DJ.

Phytother Res. 2019 Sep;33(9):2337-2346. doi: 10.1002/ptr.6415. Epub 2019 Jun 21.

PMID:
31225674
12.

Multi-zonal computer-generated holograms for high-precision optical adjustment purposes: part I: sensitivity and optical performance.

Bodendorf C, Grupp F, Bode A, Asfour JM.

Opt Express. 2019 May 13;27(10):13637-13652. doi: 10.1364/OE.27.013637.

PMID:
31163824
13.

EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter.

Shi F, Zhou M, Shang L, Du Q, Li Y, Xie L, Liu X, Tang M, Luo X, Fan J, Zhou J, Gao Q, Qiu S, Wu W, Zhang X, Bode AM, Cao Y.

Theranostics. 2019 Apr 13;9(9):2424-2438. doi: 10.7150/thno.30941. eCollection 2019.

14.

Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.

Xie X, Zu X, Liu F, Wang T, Wang X, Chen H, Liu K, Wang P, Liu F, Zheng Y, Bode AM, Dong Z, Kim DJ.

Mol Carcinog. 2019 Jul;58(7):1248-1259. doi: 10.1002/mc.23007. Epub 2019 May 17.

PMID:
31100197
15.

Inhibition of LTA4H by bestatin in human and mouse colorectal cancer.

Zhao S, Yao K, Li D, Liu K, Jin G, Yan M, Wu Q, Chen H, Shin SH, Bai R, Wang G, Bode AM, Dong Z, Guo Z, Dong Z.

EBioMedicine. 2019 Jun;44:361-374. doi: 10.1016/j.ebiom.2019.05.008. Epub 2019 May 10.

16.

Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer.

Zhao R, Huang H, Choi BY, Liu X, Zhang M, Zhou S, Song M, Yin F, Chen H, Shim JH, Bode AM, Dong Z, Lee MH.

Phytomedicine. 2019 Aug;61:152813. doi: 10.1016/j.phymed.2018.12.036. Epub 2018 Dec 31.

PMID:
31035049
17.

PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation.

Du Q, Tan Z, Shi F, Tang M, Xie L, Zhao L, Li Y, Hu J, Zhou M, Bode A, Luo X, Cao Y.

Cancer Sci. 2019 Jun;110(6):2050-2062. doi: 10.1111/cas.14011. Epub 2019 May 3.

18.

Analysis of hydrophobic and hydrophilic moments of short penetrating peptides for enhancing mitochondrial localization: prediction and validation.

Pirisinu M, Blasco P, Tian X, Sen Y, Bode AM, Liu K, Dong Z.

FASEB J. 2019 Jul;33(7):7970-7984. doi: 10.1096/fj.201802748RR. Epub 2019 Mar 27.

PMID:
30917009
19.

The PGC-1/ERR network and its role in precision oncology.

De Vitto H, Bode AM, Dong Z.

NPJ Precis Oncol. 2019 Mar 21;3:9. doi: 10.1038/s41698-019-0081-6. eCollection 2019. Review.

20.

CRISPR/Cas9 - An evolving biological tool kit for cancer biology and oncology.

Tian X, Gu T, Patel S, Bode AM, Lee MH, Dong Z.

NPJ Precis Oncol. 2019 Mar 18;3:8. doi: 10.1038/s41698-019-0080-7. eCollection 2019. Review.

21.

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo.

Liu X, Song M, Wang P, Zhao R, Chen H, Zhang M, Shi Y, Liu K, Liu F, Yang R, Li E, Bode AM, Dong Z, Lee MH.

Int J Cancer. 2019 Aug 15;145(4):1007-1019. doi: 10.1002/ijc.32285. Epub 2019 Apr 3.

22.

Posttranslational regulation of PGC-1α and its implication in cancer metabolism.

Luo X, Liao C, Quan J, Cheng C, Zhao X, Bode AM, Cao Y.

Int J Cancer. 2019 Sep 15;145(6):1475-1483. doi: 10.1002/ijc.32253. Epub 2019 Mar 26. Review.

23.

Temporal variability of diazotroph community composition in the upwelling region off NW Iberia.

Moreira-Coello V, Mouriño-Carballido B, Marañón E, Fernández-Carrera A, Bode A, Sintes E, Zehr JP, Turk-Kubo K, Varela MM.

Sci Rep. 2019 Mar 6;9(1):3737. doi: 10.1038/s41598-019-39586-4.

24.

AKT as a Therapeutic Target for Cancer.

Song M, Bode AM, Dong Z, Lee MH.

Cancer Res. 2019 Mar 15;79(6):1019-1031. doi: 10.1158/0008-5472.CAN-18-2738. Epub 2019 Feb 26. Review.

PMID:
30808672
25.

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode AM, Guo Z, Dong Z.

Mol Carcinog. 2019 Jun;58(6):1056-1067. doi: 10.1002/mc.22993. Epub 2019 Mar 1.

PMID:
30790360
26.

Defining the impact of mutation accumulation on replicative lifespan in yeast using cancer-associated mutator phenotypes.

Lee MB, Dowsett IT, Carr DT, Wasko BM, Stanton SG, Chung MS, Ghodsian N, Bode A, Kiflezghi MG, Uppal PA, Grayden KA, Elala YC, Tang TT, Tran NHB, Tran THB, Diep AB, Hope M, Promislow DEL, Kennedy SR, Kaeberlein M, Herr AJ.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3062-3071. doi: 10.1073/pnas.1815966116. Epub 2019 Feb 4.

27.

3,3'-Diindolylmethane inhibits patient-derived xenograft colon tumor growth by targeting COX1/2 and ERK1/2.

Tian X, Liu K, Zu X, Ma F, Li Z, Lee M, Chen H, Li Y, Zhao Y, Liu F, Oi N, Bode AM, Dong Z, Kim DJ.

Cancer Lett. 2019 Apr 28;448:20-30. doi: 10.1016/j.canlet.2019.01.031. Epub 2019 Feb 1.

PMID:
30716361
28.

Taurine Is a Major Carbon and Energy Source for Marine Prokaryotes in the North Atlantic Ocean off the Iberian Peninsula.

Clifford EL, Varela MM, De Corte D, Bode A, Ortiz V, Herndl GJ, Sintes E.

Microb Ecol. 2019 Aug;78(2):299-312. doi: 10.1007/s00248-019-01320-y. Epub 2019 Jan 21.

29.

Gossypin inhibits gastric cancer growth by direct targeting of AURKA and RSK2.

Wang L, Wang X, Chen H, Zu X, Ma F, Liu K, Bode AM, Dong Z, Kim DJ.

Phytother Res. 2019 Mar;33(3):640-650. doi: 10.1002/ptr.6253. Epub 2018 Dec 10.

PMID:
30536456
30.

Ethyl gallate as a novel ERK1/2 inhibitor suppresses patient-derived esophageal tumor growth.

Liu F, Zu X, Xie X, Liu K, Chen H, Wang T, Liu F, Bode AM, Zheng Y, Dong Z, Kim DJ.

Mol Carcinog. 2019 Apr;58(4):533-543. doi: 10.1002/mc.22948. Epub 2018 Dec 21.

PMID:
30499613
31.

Outcome of subtrochanteric femur resection in patients with spinal cord injuries.

Ohlmeier M, Bode A, Suero EM, Grasmücke D, Aach M, Meindl R, Schildhauer TA, Citak M.

J Wound Care. 2018 Nov 2;27(11):774-778. doi: 10.12968/jowc.2018.27.11.774.

PMID:
30398931
32.

Gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo.

Xie X, Liu K, Liu F, Chen H, Wang X, Zu X, Ma X, Wang T, Wu Q, Zheng Y, Bode AM, Dong Z, Kim DJ.

Cancer Lett. 2019 Feb 1;442:126-136. doi: 10.1016/j.canlet.2018.10.016. Epub 2018 Nov 2.

PMID:
30391783
33.

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2019 Jan;41(1):718. doi: 10.3892/or.2018.6802. Epub 2018 Oct 17.

34.

Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2.

Wang L, Zhang Y, Liu K, Chen H, Yang R, Ma X, Kim HG, Bode AM, Kim DJ, Dong Z.

Oncotarget. 2018 Feb 6;9(76):34200-34212. doi: 10.18632/oncotarget.24409. eCollection 2018 Sep 28.

35.

Mitochondrial network structure homeostasis and cell death.

Xie LL, Shi F, Tan Z, Li Y, Bode AM, Cao Y.

Cancer Sci. 2018 Dec;109(12):3686-3694. doi: 10.1111/cas.13830. Epub 2018 Nov 16. Review.

36.

Toward a mechanistic understanding of trophic structure: inferences from simulating stable isotope ratios.

Flynn KJ, Mitra A, Bode A.

Mar Biol. 2018;165(9):147. doi: 10.1007/s00227-018-3405-0. Epub 2018 Aug 23.

37.

Recent advances in precision oncology research.

Bode AM, Dong Z.

NPJ Precis Oncol. 2018 Apr 16;2:11. doi: 10.1038/s41698-018-0055-0. eCollection 2018. No abstract available.

38.

Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer.

Li J, He Y, Tan Z, Lu J, Li L, Song X, Shi F, Xie L, You S, Luo X, Li N, Li Y, Liu X, Tang M, Weng X, Yi W, Fan J, Zhou J, Qiang G, Qiu S, Wu W, Bode AM, Cao Y.

Theranostics. 2018 Jul 16;8(15):4050-4061. doi: 10.7150/thno.21524. eCollection 2018.

39.

The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K.

Zhang T, Wang Q, Fredimoses M, Gao G, Wang K, Chen H, Wang T, Oi N, Zykova TA, Reddy K, Yao K, Ma W, Chang X, Lee MH, Rathore MG, Bode AM, Ashida H, Lippman SM, Dong Z.

Cancer Prev Res (Phila). 2018 Oct;11(10):607-620. doi: 10.1158/1940-6207.CAPR-18-0092. Epub 2018 Jul 6.

40.

Targeting PRPK and TOPK for skin cancer prevention and therapy.

Roh E, Lee MH, Zykova TA, Zhu F, Nadas J, Kim HG, Bae KB, Li Y, Cho YY, Curiel-Lewandrowski C, Einspahr J, Dickinson SE, Bode AM, Dong Z.

Oncogene. 2018 Oct;37(42):5633-5647. doi: 10.1038/s41388-018-0350-9. Epub 2018 Jun 14.

41.

Addressing the challenges of applying precision oncology.

Shin SH, Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Sep 4;1(1):28. doi: 10.1038/s41698-017-0032-z. eCollection 2017. Review.

42.

DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma.

Luo X, Hong L, Cheng C, Li N, Zhao X, Shi F, Liu J, Fan J, Zhou J, Bode AM, Cao Y.

Cell Death Dis. 2018 May 23;9(6):619. doi: 10.1038/s41419-018-0662-2.

43.

Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.

Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y.

Cancer Sci. 2018 Jul;109(7):2101-2108. doi: 10.1111/cas.13634. Epub 2018 Jun 13. Review.

44.

TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis.

Wang Q, Gao G, Zhang T, Yao K, Chen H, Park MH, Yamamoto H, Wang K, Ma W, Malakhova M, Bode AM, Dong Z.

Cancer Res. 2018 Jul 15;78(14):3982-3994. doi: 10.1158/0008-5472.CAN-18-0429. Epub 2018 May 10.

45.

Racial and gender disparities in violent trauma: Results from the NEMSIS database.

Bode AD, Singh M, Andrews JR, Baez AA.

Am J Emerg Med. 2019 Jan;37(1):53-55. doi: 10.1016/j.ajem.2018.04.049. Epub 2018 Apr 23.

PMID:
29724579
46.

Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.

Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, Shi F, Li N, Li Y, Du Q, Lu J, Weng X, Yi W, Zhang H, Fan J, Zhou J, Gao Q, Onuchic JN, Bode AM, Luo X, Cao Y.

Theranostics. 2018 Mar 22;8(9):2329-2347. doi: 10.7150/thno.21451. eCollection 2018.

47.

Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo.

Song M, Liu X, Liu K, Zhao R, Huang H, Shi Y, Zhang M, Zhou S, Xie H, Chen H, Li Y, Zheng Y, Wu Q, Liu F, Li E, Bode AM, Dong Z, Lee MH.

Mol Cancer Ther. 2018 Jul;17(7):1540-1553. doi: 10.1158/1535-7163.MCT-17-0823. Epub 2018 Apr 25.

48.

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2018 Sep;40(3):1545-1553. doi: 10.3892/or.2018.6313. Epub 2018 Mar 14. Erratum in: Oncol Rep. 2019 Jan;41(1):718.

49.

RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation.

Yao K, Lee SY, Peng C, Lim DY, Yamamoto H, Ryu J, Lim TG, Chen H, Jin G, Zhao Z, Han Y, Ma WY, Bode AM, Dong Z.

Oncogene. 2018 Jun;37(26):3501-3513. doi: 10.1038/s41388-018-0167-6. Epub 2018 Mar 22.

50.

Targeting PRPK Function Blocks Colon Cancer Metastasis.

Zykova T, Zhu F, Wang L, Li H, Lim DY, Yao K, Roh E, Yoon SP, Kim HG, Bae KB, Wen W, Shin SH, Nadas J, Li Y, Ma W, Bode AM, Dong Z.

Mol Cancer Ther. 2018 May;17(5):1101-1113. doi: 10.1158/1535-7163.MCT-17-0628. Epub 2018 Feb 26.

Supplemental Content

Support Center